Actively Recruiting
Evaluation of CTAP101 Extended-release Capsules for Safety, Pharmacokinetics, and Tolerability in Children With Secondary Hyperparathyroidism and Chronic Kidney Disease
Led by OPKO Health, Inc. · Updated on 2026-08-20
40
Participants Needed
5
Research Sites
43 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and how CTAP101 Capsules work in children under 18 years old who have secondary hyperparathyroidism along with stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The study specifically aims to understand how the body absorbs and processes CTAP101 and its effects over time while monitoring any side effects. Participants will take CTAP101 Capsules daily at bedtime for 8 weeks. Two groups will receive different doses one group 30 mcg and the other group either 30 mcg or 60 mcg. The study is open-label and randomized, meaning participants are assigned to groups in sequence without masking. This trial is conducted across multiple centers and focuses on pediatric patients weighing at least 40 kg. During the study, participants will be monitored through blood tests measuring drug clearance, distribution, and half-life, as well as safety assessments for any adverse events over up to 14 weeks. Participants must comply with study visits and procedures, including stopping certain vitamin D or bone metabolism therapies before starting. The study lasts for several weeks, with researchers closely observing how the capsules affect the participants condition and safety.
CONDITIONS
Brief Title
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
Research Team
O
OPKO Health
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here